Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2017 June;72(3) > Minerva Chirurgica 2017 June;72(3):206-18

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA CHIRURGICA

A Journal on Surgery


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,115


eTOC

 

REVIEW  


Minerva Chirurgica 2017 June;72(3):206-18

DOI: 10.23736/S0026-4733.17.07311-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena

Jose FERRI 1, Yanina DOCKX 1, Luisa VONGHIA 2, Konstantinos PAPADIMITRIOU 1, Marika RASSCHAERT 1, Sven FRANCQUE 1, Marc PEETERS 1, Christian ROLFO 1

1 Phase I, Early Clinical Trials Unit, Antwerp University Hospital and Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium; 2 Department of Gastroenterology and Hepathology, Antwerp University Hospital, Antwerp, Belgium


PDF  


Treatment of advanced hepatocellular carcinoma remains a challenge, with discouraging results in terms of survival. Following the approval of the multikinase inhibitor sorafenib, a large number of molecular targeted agents have been tested, but many have failed to demonstrate significant efficacy in clinical trials. However, the deeper knowledge in HCC pathogenesis achieved through the years has enabled us to explore new targetable pathways as well as biomarkers that could lead to treatment personalization. In this review, we provide a comprehensive update of the most recent data regarding new drugs under investigation ‒ some like regorafenib, very close to its approval ‒ and new possible targets for future treatments.


KEY WORDS: Hepatocellular carcinoma - Molecular targeted therapy - Biomarkers

top of page

Publication History

Issue published online: May 4, 2017
Article first published online: February 14, 2017

Cite this article as

Ferri J, Dockx Y, Vonghia L, Papadimitriou K, Rasschaert M, Francque S, et al. Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena. Minerva Chir 2017;72:206-18. DOI: 10.23736/S0026-4733.17.07311-4

Corresponding author e-mail

christian.rolfo@uza.be